The high ratings for professionalism and overall satisfaction are encouraging and provide a positive basis upon which to further develop
the appropriate management of minor ailments in this setting. 1. Paudyal V, Watson MC, Sach T, Porteous T, Bond CM, Wright D, Cleland J, Barton G, Holland, R. Are pharmacy-based Minor Ailment Schemes a substitute for other service providers? A systematic review. Br http://www.selleckchem.com/products/Vorinostat-saha.html J Gen Pract (in press) 2. Silverman J., Kurtz S.M., Draper J. Skills for Communicating with Patients. 2nd ed. Oxford: Radcliffe Publishing; 2005 Erika Kennington1, Ross Leach2, Elizabeth Shepherd4, Deborah Evans3, Gul Root2, Catherine Duggan1 1Royal Pharmaceutical Society, London, UK, 2Department of Health, London, UK, 3National Pharmacy Association, London, UK, 4Consultant in Community selleck chemical Pharmacy, n/a, UK Healthy Living Pharmacy (HLP) delivery of Stop Smoking services is widespread but is it effective across the country? Evaluation in nine areas showed that more people successfully quit smoking in HLPs than non-HLPs, and economic evaluation estimated a cost per quit range of £64-217, depending on
the pharmacy skill mix employed. HLPs appear to be more successful in helping people engage with Stop Smoking Services whilst maintaining quit rates, and appear to deliver the service in a cost-effective manner. The HLP approach is a tiered commissioning framework aimed at achieving consistent delivery of a broad range of high quality services through community pharmacies to meet local need, improving the health and wellbeing of the local population and helping to reduce health inequalities. Following positive evaluation of the Portsmouth HLP in 2009/10, a roll-out programme was created to support HLP implementation in 20 pathfinder areas across England with the aim of evaluating HLP at a national level. One service delivered through HLP is Stop Smoking and this study aimed to assess whether there is better uptake and delivery of this service in HLPs compared to baseline, and whether its delivery through HLP is cost-effective. Centralised evaluation of HLP services was not attempted
because of the wide variation in service specifications, data collected mafosfamide and timings of HLP implementation programmes. Service uptake, activity and outcomes were therefore evaluated locally by each pathfinder area, using either a before and after comparison or an HLP versus non-HLP comparison. Pathfinders were provided with a reporting template to support their analysis and interpretation, and encouraged to describe a core set of reporting outcomes which included number of quits set, number of 4-week quits achieved and quit rate. A separate survey of contractors was undertaken which collected data on the skill mix and time spent delivering the service. NRES guidance deemed this to be service evaluation and therefore ethical approval was not required. The average number quit dates set per pharmacy was 27.3 in HLPs compared to 17.